Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Desmond Curran

Showing results (61-70 of 85) with videos related to

Pageof 9
Sort By:
European Journal of Cancer (Oxford, England : 1990)|November 3, 2012
Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorinIstván Láng, Claus-Henning Köhne, Gunnar Folprecht, et al.
Human Vaccines & Immunotherapeutics|January 10, 2019
Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine liveDesmond Curran, Brandon J Patterson, Desiree Van Oorschot, et al.
Vaccines|November 25, 2023
Knowledge, Attitudes, and Practices of European Healthcare Professionals towards Hepatitis A and Hepatitis B Vaccination in at-Risk AdultsDasha Shamarina, Martina Sluga-O'Callaghan, George Kassianos, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|July 1, 2021
Estimated Public Health Impact of the Recombinant Zoster VaccineBrandon J Patterson, Philip O Buck, Desmond Curran, et al.
Pharmacoeconomics - Open|November 2, 2023
Cost-Effectiveness of Recombinant Zoster Vaccine for the Prevention of Herpes Zoster in Hematopoietic Stem Cell Transplant Recipients and Other Immunocompromised Adults in the United StatesAhmed Salem, Elizabeth M La, Desmond Curran, et al.
Pain|September 6, 2022
Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trialsJoon Hyung Kim, Robert Johnson, Martina Kovac, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|July 2, 2009
Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trialDesmond Curran, Carmelo Pozzo, Jerzy Zaluski, et al.
Human Vaccines & Immunotherapeutics|March 7, 2023
Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancerDesmond Curran, Brandon J Patterson, Justin Carrico, et al.
Human Vaccines & Immunotherapeutics|August 24, 2019
The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in ItalyAntonio Volpi, Sara Boccalini, Silvia Dari, et al.
Dermatology and Therapy|November 21, 2018
Burden of Herpes Zoster in the Japanese Population with Immunocompromised/Chronic Disease Conditions: Results from a Cohort Study Claims Database from 2005-2014Shinichi Imafuku, Taizo Matsuki, Akiko Mizukami, et al.
Pageof 9

Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
European Journal of Cancer (Oxford, England : 1990)|November 3, 2012
Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorinIstván Láng, Claus-Henning Köhne, Gunnar Folprecht, et al.
Human Vaccines & Immunotherapeutics|January 10, 2019
Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine liveDesmond Curran, Brandon J Patterson, Desiree Van Oorschot, et al.
Vaccines|November 25, 2023
Knowledge, Attitudes, and Practices of European Healthcare Professionals towards Hepatitis A and Hepatitis B Vaccination in at-Risk AdultsDasha Shamarina, Martina Sluga-O'Callaghan, George Kassianos, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|July 1, 2021
Estimated Public Health Impact of the Recombinant Zoster VaccineBrandon J Patterson, Philip O Buck, Desmond Curran, et al.
Pharmacoeconomics - Open|November 2, 2023
Cost-Effectiveness of Recombinant Zoster Vaccine for the Prevention of Herpes Zoster in Hematopoietic Stem Cell Transplant Recipients and Other Immunocompromised Adults in the United StatesAhmed Salem, Elizabeth M La, Desmond Curran, et al.
Pain|September 6, 2022
Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trialsJoon Hyung Kim, Robert Johnson, Martina Kovac, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|July 2, 2009
Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trialDesmond Curran, Carmelo Pozzo, Jerzy Zaluski, et al.
Human Vaccines & Immunotherapeutics|March 7, 2023
Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancerDesmond Curran, Brandon J Patterson, Justin Carrico, et al.
Human Vaccines & Immunotherapeutics|August 24, 2019
The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in ItalyAntonio Volpi, Sara Boccalini, Silvia Dari, et al.
Dermatology and Therapy|November 21, 2018
Burden of Herpes Zoster in the Japanese Population with Immunocompromised/Chronic Disease Conditions: Results from a Cohort Study Claims Database from 2005-2014Shinichi Imafuku, Taizo Matsuki, Akiko Mizukami, et al.
Pageof 9